Roflumilast, a long-acting selective inhibitor of the phosphodiesterase-4 (PDE4) enzyme, was shown to have anti-inflammatory effects in lung fibroblast models, and it is prescribed for other conditions, such as chronic obstructive pulmonary disease (COPD) [20,21]. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.